Canlyniadau Chwilio - Faries, Douglas

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder gan Liu, Xianchen, Chen, Yi, Faries, Douglas E

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Predictors of duloxetine adherence and persistence in patients with fibromyalgia gan Cui, Zhanglin, Zhao, Yang, Novick, Diego, Faries, Douglas

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example gan Faries, Douglas E, Nyhuis, Allen W, Ascher-Svanum, Haya

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A comparison of reweighting estimators of average treatment effects in real world populations gan Lin, Chen‐Yen, Kaizar, Eloise, Faries, Douglas, Johnston, Joseph

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia gan Ascher-Svanum, Haya, Zhu, Baojin, Faries, Douglas, Ernst, Frank R

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics gan Faries, Douglas, Ascher-Svanum, Haya, Zhu, Baojin, Correll, Christoph, Kane, John

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patients gan Ascher-Svanum, Haya, Peng, Xiaomei, Faries, Douglas, Montgomery, William, Haddad, Peter M

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia gan Faries, Douglas E, Ascher-Svanum, Haya, Nyhuis, Allen W, Kinon, Bruce J

Cael y testun llawn Cael y testun llawn Cael y testun llawn

A cross-validation of the provisional diagnostic instrument (PDI-4) gan Faries, Douglas E, Houston, John P, Sulcs, Ellen M, Swindle, Ralph W

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia gan Ascher-Svanum, Haya, Zhu, Baojin, Faries, Douglas, Landbloom, Ron, Swartz, Marvin, Swanson, Jeff

Cael y testun llawn Cael y testun llawn Cael y testun llawn

The Burden of Depressive Symptoms in the Long-Term Treatment of Patients With Schizophrenia gan Conley, Robert R., Ascher-Svanum, Haya, Zhu, Baojin, Faries, Douglas, Kinon, Bruce J.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia gan Ascher-Svanum, Haya, Zhu, Baojin, Faries, Douglas E, Furiak, Nicolas M, Montgomery, William

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia gan Peng, Xiaomei, Ascher-Svanum, Haya, Faries, Douglas, Conley, Robert R, Schuh, Kory J

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study gan Cuyún Carter, Gebra B, Milton, Denái R, Ascher-Svanum, Haya, Faries, Douglas E

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Practical recommendations on double score matching for estimating causal effects gan Zhang, Yunshu, Yang, Shu, Ye, Wenyu, Faries, Douglas E., Lipkovich, Ilya, Kadziola, Zbigniew

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Cost of antipsychotic polypharmacy in the treatment of schizophrenia gan Zhu, Baojin, Ascher-Svanum, Haya, Faries, Douglas E, Correll, Christoph U, Kane, John M

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Local control for identifying subgroups of interest in observational research: persistence of treatment for major depressive disorder gan Faries, Douglas E., Chen, Yi, Lipkovich, Ilya, Zagar, Anthony, Liu, Xianchen, Obenchain, Robert L.

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Costs of treating patients with schizophrenia who have illness-related crisis events gan Zhu, Baojin, Ascher-Svanum, Haya, Faries, Douglas E, Peng, Xiaomei, Salkever, David, Slade, Eric P

Cael y testun llawn Cael y testun llawn Cael y testun llawn

Patient perception of medication benefit and early treatment discontinuation in a 1-year study of patients with schizophrenia gan Liu-Seifert, Hong, Adams, David H, Ascher-Svanum, Haya, Faries, Douglas E, Kinon, Bruce J

Cael y testun llawn Cael y testun llawn

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia gan Ascher-Svanum, Haya, Nyhuis, Allen W, Faries, Douglas E, Ball, Daniel E, Kinon, Bruce J

Cael y testun llawn Cael y testun llawn Cael y testun llawn